Outlook Therapeutics Inc OTLK:NASDAQ

RT Quote | NASDAQ | USD
Last | 10/06/22 EDT
1.26quote price arrow up+0.01 (+0.80%)
Volume
691,075
52 week range
0.68 - 2.31
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.26
  • 52 Week High2.31
  • 52 Week High Date10/08/21
  • 52 Week Low0.68
  • 52 Week Low Date05/31/22

Key Stats

  • Market Cap284.94M
  • Shares Out226.14M
  • 10 Day Average Volume0.54M
  • Dividend-
  • Dividend Yield-
  • Beta0.73
  • YTD % Change-7.35

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.26
  • 52 Week High2.31
  • 52 Week High Date10/08/21
  • 52 Week Low0.68
  • 52 Week Low Date05/31/22
  • Market Cap284.94M
  • Shares Out226.14M
  • 10 Day Average Volume0.54M
  • Dividend-
  • Dividend Yield-
  • Beta0.73
  • YTD % Change-7.35

RATIOS/PROFITABILITY

  • EPS (TTM)-0.33
  • P/E (TTM)-3.87
  • Fwd P/E (NTM)-4.98
  • EBITDA (TTM)-62.315M
  • ROE (TTM)-396.64%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-605.00%
  • Debt To Equity (MRQ)52.19%

EVENTS

  • Earnings Date12/20/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Outlook Therapeutics Inc

 

Profile

MORE
Outlook Therapeutics, Inc. (Outlook) is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. ONS-5010, is the Company's product candidate, which is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases. Bevacizumab is a...
Ralph Thurman
Independent Executive Chairman of the Board
C. Russell Trenary III
President, Chief Executive Officer, Director
Terry Dagnon
Chief Operations Officer
Lawrence Kenyon
Chief Financial Officer, Executive Vice President, Treasurer, Company Secretary, Director
Address
485 Route 1 South, Building F, Suite 320
Iselin, NJ
08830
United States

Top Peers

SYMBOLLASTCHG%CHG
VXRT
Vaxart Inc
1.99-0.15-7.01%
OPT
Opthea Ltd
5.54-0.25-4.40%
MIST
Milestone Pharmaceuticals Inc
9.28+0.32+3.57%
BMEA
Biomea Fusion Inc
10.28-0.07-0.68%
NAUT
Nautilus Biotechnology Inc
2.06-0.11-5.07%